ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical management of haemophilia B requires precise factor IX replacement to ensure adequate haemostasis while optimizing factor consumption. Extended half-life rFIX-FP simplifies perioperative management but exhibits substantial pharmacokinetic variability. PK-guided dosing is recommended by WFH guidelines, yet validated tools for perioperative rFIX-FP individualization are lacking.
objectivesTo validate a population PK model under perioperative conditions and evaluate Hemoptidose, a model-informed precision dosing (MIPD) platform, for individualizing rFIX-FP therapy during surgery.
methodsWe retrospectively analyzed 24 surgeries in haemophilia B patients treated with rFIX-FP. Predictive performance was assessed at population level and after Bayesian individualization with varying numbers of FIX samples. Actual perioperative consumption was retrospectively compared with Hemoptidose-recommended doses.
resultsThe population PK model demonstrated robust perioperative performance. Population predictions yielded a mean absolute error (MAE) of 20.6%; after Bayesian updating, accuracy improved with MAE of 10.0%. Prediction error decreased from 20.6% without monitoring to 14% with three samples. Retrospective analysis indicated a potential 49% reduction in factor consumption with model-guided dosing compared to empirical regimens (p < 0.001).
conclusionsThe population PK model retains valid predictive performance in surgical settings. Two to three FIX measurements enable reliable individualization. The substantial discrepancy between empirical and model-guided dosing highlights major optimization potential. Hemoptidose provides accessible MIPD implementation for perioperative rFIX-FP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.